PROF vs ISRG vs NVCR vs AEYE vs EDAP

For growth investors, Profound Medical Corp.

(PROF) is the stronger pick with 61. 1% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Profound Medical Corp. (PROF) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Profound Medical Corp. (PROF) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Profound Medical Corp.

(PROF) is the cheapest at 5. 1x versus Intuitive Surgical, Inc. at 57. 6x.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus PROF's -26. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edap Tms S.

a. (EDAP) is the lower-risk stock at 0. 77β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 199% more volatile than EDAP relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 143% for Edap Tms S. a. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Profound Medical Corp.

(PROF) is pulling ahead at 61. 1% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Profound Medical Corp. grew EPS 231. 8% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, PROF leads at 34. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Profound Medical Corp.

(PROF) is the more profitable company, earning 258. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 258. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -256. 3% for PROF. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Intuitive Surgical, Inc.

(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PROF (Healthcare) and ISRG (Healthcare) and NVCR (Healthcare) and AEYE (Technology) and EDAP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PROF is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; EDAP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.